Overview

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to assess the effect of BMS-986142 on the single-dose PK parameters of montelukast, flurbiprofen, omeprazole, midazolam, and digoxin, probe drugs for (cytochome P450) CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein (P-gp), respectively.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Digoxin
Flurbiprofen
Midazolam
Montelukast
Omeprazole